申请人:Pfizer Inc.
公开号:US03991207A1
公开(公告)日:1976-11-09
Substituted 1,2,3,4-tetrahydro-1-naphthylamines, or their acid addition salts, as potentiating agents in combination therapy with L-Dopa for control of the symptoms of Parkinson's disease. N,N-Dimethyl-5-methoxy-8-chloro-1,2,3,4-tetrahydro-1-naphthylamine is the preferred embodiment.
使用1,2,3,4-四氢基-1-萘胺或其酸加盐作为L-Dopa联合治疗帕金森病症状的增强剂。N,N-二甲基-5-甲氧基-8-氯-1,2,3,4-四氢基-1-萘胺是首选实施例。